Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELVN NASDAQ:GMTX NASDAQ:GPCR NASDAQ:TBPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELVNEnliven Therapeutics$52.95+0.3%$45.49$14.78▼$54.88$3.22B0.241.18 million shs368,655 shsGMTXGemini Therapeutics$74.12-2.3%$71.63$1.16▼$14.10$3.21B-0.12189,291 shs403,436 shsGPCRStructure Therapeutics$49.12-3.3%$45.42$15.80▼$94.90$3.61B-1.5679,096 shs655,406 shsTBPHTheravance Biopharma$16.86$16.66$10.82▼$21.03$869.18M0.17943,275 shs652,200 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELVNEnliven Therapeutics+0.27%-0.47%+10.84%+19.66%+136.91%GMTXGemini Therapeutics+2.07%+3.25%+7.68%+10.18%+24.89%GPCRStructure Therapeutics-3.31%+1.32%+1.99%+7.98%+170.48%TBPHTheravance Biopharma0.00%-0.41%-2.37%+2.43%+49.20%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELVNEnliven Therapeutics$52.95+0.3%$45.49$14.78▼$54.88$3.22B0.241.18 million shs368,655 shsGMTXGemini Therapeutics$74.12-2.3%$71.63$1.16▼$14.10$3.21B-0.12189,291 shs403,436 shsGPCRStructure Therapeutics$49.12-3.3%$45.42$15.80▼$94.90$3.61B-1.5679,096 shs655,406 shsTBPHTheravance Biopharma$16.86$16.66$10.82▼$21.03$869.18M0.17943,275 shs652,200 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELVNEnliven Therapeutics+0.27%-0.47%+10.84%+19.66%+136.91%GMTXGemini Therapeutics+2.07%+3.25%+7.68%+10.18%+24.89%GPCRStructure Therapeutics-3.31%+1.32%+1.99%+7.98%+170.48%TBPHTheravance Biopharma0.00%-0.41%-2.37%+2.43%+49.20%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELVNEnliven Therapeutics 2.86Moderate Buy$70.5033.14% UpsideGMTXGemini Therapeutics 0.00N/AN/AN/AGPCRStructure Therapeutics 2.89Moderate Buy$110.55125.05% UpsideTBPHTheravance Biopharma 2.00Hold$19.4015.07% UpsideCurrent Analyst Ratings BreakdownLatest TBPH, GPCR, GMTX, and ELVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026ELVNEnliven Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$59.00 ➝ $67.007/17/2026ELVNEnliven Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026GPCRStructure Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/9/2026ELVNEnliven Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $64.007/7/2026TBPHTheravance Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$15.00 ➝ $17.007/1/2026ELVNEnliven Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $80.006/29/2026TBPHTheravance Biopharma BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral6/29/2026ELVNEnliven Therapeutics JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$45.00 ➝ $70.006/29/2026TBPHTheravance Biopharma JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold6/11/2026GPCRStructure Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$100.00 ➝ $70.006/9/2026ELVNEnliven Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.00(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELVNEnliven TherapeuticsN/AN/AN/AN/A$7.74 per shareN/AGMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/AGPCRStructure TherapeuticsN/AN/AN/AN/A$24.99 per shareN/ATBPHTheravance Biopharma$107.46M8.09N/AN/A$5.86 per share2.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELVNEnliven Therapeutics-$103.69M-$1.67N/AN/AN/AN/A-21.04%-20.41%8/12/2026 (Estimated)GMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/AGPCRStructure Therapeutics-$141.20M-$0.87N/AN/AN/AN/A-24.91%-23.67%8/6/2026 (Estimated)TBPHTheravance Biopharma$105.89M$2.207.6662.44N/A104.34%18.84%10.94%8/11/2026 (Estimated)Latest TBPH, GPCR, GMTX, and ELVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026ELVNEnliven Therapeutics-$0.38N/AN/AN/AN/AN/A8/11/2026Q2 2026TBPHTheravance Biopharma$0.0725N/AN/AN/A$22.49 millionN/A8/6/2026Q2 2026GPCRStructure Therapeutics-$0.39N/AN/AN/AN/AN/A5/7/2026Q1 2026ELVNEnliven Therapeutics-$0.44-$0.38+$0.06-$0.38N/AN/A5/7/2026Q1 2026GPCRStructure Therapeutics-$0.39-$0.35+$0.04-$0.35$11.11 millionN/A5/7/2026Q1 2026TBPHTheravance Biopharma$0.0280-$0.10-$0.1280-$0.10$17.78 million$17.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthELVNEnliven TherapeuticsN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELVNEnliven TherapeuticsN/A40.3240.32GMTXGemini TherapeuticsN/A71.4971.49GPCRStructure TherapeuticsN/A26.1626.16TBPHTheravance BiopharmaN/A13.1413.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELVNEnliven Therapeutics95.08%GMTXGemini Therapeutics75.42%GPCRStructure Therapeutics91.78%TBPHTheravance Biopharma99.10%Insider OwnershipCompanyInsider OwnershipELVNEnliven Therapeutics3.00%GMTXGemini Therapeutics12.90%GPCRStructure Therapeutics5.50%TBPHTheravance Biopharma7.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELVNEnliven Therapeutics5060.91 million59.08 millionOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableGPCRStructure Therapeutics13671.07 million67.17 millionOptionableTBPHTheravance Biopharma11051.55 million47.61 millionOptionableTBPH, GPCR, GMTX, and ELVN HeadlinesRecent News About These CompaniesPrecision Wealth Strategies LLC Takes $1.02 Million Position in Theravance Biopharma, Inc. $TBPHJuly 19, 2026 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Shares Cross Above 50 Day Moving Average - Here's WhyJuly 17, 2026 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives $19.40 Average PT from AnalystsJuly 16, 2026 | americanbankingnews.comTheravance Biopharma Stock Dividends | NASDAQ:TBPH | BenzingaJuly 13, 2026 | benzinga.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Hold" by AnalystsJuly 9, 2026 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Major Shareholder Sells $428,712.51 in StockJuly 2, 2026 | insidertrades.comTheravance Stock Down 3% After Zymeworks Announces BuyoutJune 30, 2026 | zacks.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH)June 29, 2026 | prnewswire.comTBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its ShareholdersJune 29, 2026 | businesswire.comShareholder Alert: Ademi LLP investigates whether Theravance Biopharma, Inc. is obtaining a Fair Price for Public ShareholdersJune 29, 2026 | prnewswire.comTheravance Biopharma, Inc.: Theravance Biopharma Enters Into Definitive Agreement To Be Acquired By Zymeworks For $17.00 Per Share In Cash Plus A Contingent Value RightJune 29, 2026 | finanznachrichten.deZymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH ShareholdersJune 29, 2026 | finance.yahoo.comZymeworks strikes $929 million deal for Theravance BiopharmaJune 29, 2026 | reuters.comZymeworks to Acquire Theravance Biopharma, Inc.June 29, 2026 | financialpost.comFTHERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHTJune 29, 2026 | prnewswire.comInsider Selling: Theravance Biopharma (NASDAQ:TBPH) SVP Sells 13,314 Shares of StockJune 18, 2026 | insidertrades.comTBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline HurdleMay 8, 2026 | zacks.comHere's Why Theravance Biopharma (TBPH) is a Strong Momentum StockMay 7, 2026 | zacks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHMay 7, 2026 | prnewswire.comTheravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 7, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 30, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTBPH, GPCR, GMTX, and ELVN Company DescriptionsEnliven Therapeutics NASDAQ:ELVN$52.95 +0.14 (+0.27%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$52.93 -0.02 (-0.04%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Gemini Therapeutics NASDAQ:GMTX$74.12 -1.74 (-2.29%) As of 07/24/2026Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Structure Therapeutics NASDAQ:GPCR$49.12 -1.68 (-3.31%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$49.18 +0.07 (+0.13%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Theravance Biopharma NASDAQ:TBPH$16.86 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$16.86 0.00 (0.00%) As of 07/24/2026 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Plugging In: How Kinder Morgan Powers Up Profits TSMC’s Price Hikes Could Show Which AI Chip Stocks Have Real Pricing Power Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
